Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ACH
ACH logo

ACH Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
3.700
Open
3.570
VWAP
3.61
Vol
774.30K
Mkt Cap
274.94M
Low
3.525
Amount
2.79M
EV/EBITDA(TTM)
5.36
Total Shares
76.58M
EV
2.04B
EV/OCF(TTM)
14.63
P/S(TTM)
0.10
Accendra Health, Inc., formerly Owens & Minor, Inc., is a provider of products, technology, and services for health beyond the hospital for millions of people each year. The Company connects patients, providers, and insurers, delivering solutions for people living with chronic, complex health conditions. It provides delivery of products, including disposable medical supplies sold directly to patients and home health agencies and is a provider of integrated home healthcare equipment and related services in the United States. It offers a range of products and services for in-home care and delivery across diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure (CPAP) and bi-level positive airway pressure devices, and patient support services). The Company also provides clinical and administrative support services and related products and supplies.
Show More

Events Timeline

(ET)
2026-05-11
06:40:00
Accendra Health Confirms FY26 Guidance for Net Revenue and Adjusted EBITDA
select
2026-05-11
06:40:00
Accendra Health Q1 Revenue at $627.8M
select
2026-02-19 (ET)
2026-02-19
16:20:00
Sees FY26 Adjusted EBITDA of $335M-$355M
select
2026-02-19
16:20:00
Accendra Health Q4 Revenue at $709M
select

News

Newsfilter
8.5
06-24Newsfilter
Accendra Health Completes Bond Exchange Offers
  • Exchange Offer Results: As of June 23, 2026, Accendra Health successfully received approximately $478.3 million in 2029 Senior Notes and $548.0 million in 2030 Senior Notes, representing 99.9% and 99.2% of the total amounts, respectively, indicating strong investor support for the company's debt restructuring.
  • New Notes Issuance: The company plans to issue $213.0 million in First Lien Notes and $698.1 million in Second Lien Notes in exchange for validly tendered Existing Notes, which is expected to enhance the capital structure and reduce financing costs.
  • Compliance Statement: The issuance of the New Notes has not been registered with the SEC, indicating the company's commitment to legal compliance while actively seeking participation from qualified investors to ensure the legality of the transactions.
  • Strategic Advisor Engagement: Ducera Securities LLC has been engaged as the financial advisor to assist the company in this debt restructuring, reflecting the company's professionalism in capital market operations and its focus on future financial health.
Newsfilter
8.5
06-10Newsfilter
Accendra Health Announces Early Results of Bond Exchange Offers
  • Successful Bond Exchange Offers: As of June 9, 2026, Accendra Health received valid tenders for approximately $478.3 million of 2029 Notes and $547.9 million of 2030 Notes, representing 99.9% and 99.2% of the total amounts, respectively, indicating strong investor interest in the new bond issuance and enhancing the company's capital structure.
  • New Bond Issuance Plan: The company plans to issue $326.25 million in aggregate principal amount of newly issued First Lien Notes, aimed at optimizing its financial condition through the introduction of new funds, which is expected to enhance the company's financial flexibility and market competitiveness.
  • Amendment of Covenant Terms: The company has obtained the necessary consents from existing bondholders to amend covenant terms to eliminate most restrictive clauses, which will facilitate greater flexibility in future mergers and financing activities, further driving business growth.
  • Timeline Adjustments: The expected early settlement date for all existing notes is set for June 15, 2026, with the expiration time for the exchange offers extended to June 23, 2026, providing investors with more opportunities to participate and potentially increasing the liquidity of the bonds.
Yahoo Finance
8.5
05-22Yahoo Finance
Accendra Health Launches Bond Exchange Offers
  • Exchange Offer Initiation: Accendra Health has announced the commencement of exchange offers for its 4.500% and 6.625% Senior Notes, aiming to replace existing notes with newly issued 9.000% and 9.750% Senior Secured Notes, thereby optimizing its capital structure and reducing financing costs.
  • New Money Notes Issuance: The company is offering $326.25 million in new money notes to incentivize existing noteholders to participate, which is expected to enhance liquidity and support future financial flexibility.
  • Covenant Amendments: The company is soliciting significant amendments to the existing notes' covenants, including the elimination of most affirmative and negative covenants, which will help improve operational flexibility and reduce compliance costs.
  • Commitment Agreement Support: The company has entered into a commitment agreement with existing noteholders, with approximately 83% of 2030 noteholders expected to participate, indicating strong market confidence in the company's strategic direction.
Yahoo Finance
9.5
05-12Yahoo Finance
Accendra Health Earnings Review: Revenue Decline and Debt Management
  • Revenue Decline: Accendra Health reported a 6.8% revenue decline in Q1, primarily due to exiting a large commercial payor, with an estimated growth of about 1% if this impact is excluded, posing challenges to the company's future revenue stability.
  • Adjusted EBITDA: The company achieved an adjusted EBITDA of $58 million, in line with expectations, indicating a relative stability in operational efficiency despite revenue pressures, reflecting its ability to maintain profitability.
  • Debt Management Plan: The company anticipates deleveraging up to $115 million through exchange offers for new notes, although it faces an estimated annual interest expense increase of about $40 million, which will negatively impact free cash flow.
  • Market Performance: Despite overall revenue decline, the sleep category achieved over 4% growth, indicating strong market demand in specific areas, suggesting potential for enhanced competitiveness through ongoing investment and innovation.
NASDAQ.COM
2.0
05-11NASDAQ.COM
Accendra Health (ACH) Q1 2026 Earnings Transcript
Newsfilter
9.5
05-11Newsfilter
Accendra Health Announces $1.5 Billion Balance Sheet Optimization
  • Financial Optimization Transaction: Accendra Health has announced a comprehensive balance sheet optimization transaction exceeding $1.5 billion with existing creditors, aimed at strengthening its balance sheet, significantly extending maturities, and reducing leverage, thereby laying a solid foundation for the company's long-term growth.
  • First Quarter Financial Results: For Q1 2026, net revenue was $627.8 million, down from $673.9 million year-over-year, although adjusted EBITDA stood at $58.4 million, indicating the company's ability to maintain profitability during its transformation into a home-based care provider.
  • Liquidity Enhancement: This transaction will enable the company to pay off its 2027 maturities and extend its revolving credit facility, providing essential liquidity to support future strategic flexibility and ensuring a competitive edge in a challenging market.
  • Investor Conference Call: Accendra Health will host an investor conference call on May 11, 2026, to discuss its first-quarter financial results, further enhancing communication with investors and boosting market confidence.
Wall Street analysts forecast ACH stock price to rise
3 Analyst Rating
Wall Street analysts forecast ACH stock price to rise
1 Buy
1 Hold
1 Sell
Hold
Current: 0.000
sliders
Low
2.50
Averages
3.50
High
4.00
Current: 0.000
sliders
Low
2.50
Averages
3.50
High
4.00
UBS
Neutral
maintain
$3
AI Analysis
2026-05-12
Reason
UBS
Price Target
$3
AI Analysis
2026-05-12
maintain
Neutral
Reason
UBS raised the firm's price target on Accendra Health to $4.50 from $3 and keeps a Neutral rating on the shares.
Citi
NULL -> Buy
upgrade
$5
2026-05-12
Reason
Citi
Price Target
$5
2026-05-12
upgrade
NULL -> Buy
Reason
Citi raised the firm's price target on Accendra Health to $5 from $3.25 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ACH
Unlock Now

Valuation Metrics

The current forward P/E ratio for Accendra Health Inc (ACH.N) is 2.86, compared to its 5-year average forward P/E of 3.02. For a more detailed relative valuation and DCF analysis to assess Accendra Health Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
3.02
Current PE
2.86
Overvalued PE
3.27
Undervalued PE
2.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
10.39
Current EV/EBITDA
14.82
Overvalued EV/EBITDA
13.27
Undervalued EV/EBITDA
7.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.08
Current PS
0.10
Overvalued PS
0.09
Undervalued PS
0.06

Financials

AI Analysis
Annual
Quarterly

Whales Holding ACH

C
Coliseum Capital Management, LLC
Holding
ACH
+17.64%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Accendra Health Inc (ACH) stock price today?

The current price of ACH is 3.59 USD — it has increased 0.28

What is Accendra Health Inc (ACH)'s business?

Accendra Health, Inc., formerly Owens & Minor, Inc., is a provider of products, technology, and services for health beyond the hospital for millions of people each year. The Company connects patients, providers, and insurers, delivering solutions for people living with chronic, complex health conditions. It provides delivery of products, including disposable medical supplies sold directly to patients and home health agencies and is a provider of integrated home healthcare equipment and related services in the United States. It offers a range of products and services for in-home care and delivery across diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure (CPAP) and bi-level positive airway pressure devices, and patient support services). The Company also provides clinical and administrative support services and related products and supplies.

What is the price predicton of ACH Stock?

Wall Street analysts forecast ACH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACH is3.50 USD with a low forecast of 2.50 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Accendra Health Inc (ACH)'s revenue for the last quarter?

Accendra Health Inc revenue for the last quarter amounts to 627.78M USD, decreased -6.84

What is Accendra Health Inc (ACH)'s earnings per share (EPS) for the last quarter?

Accendra Health Inc. EPS for the last quarter amounts to -0.08 USD, decreased -75.00

How many employees does Accendra Health Inc (ACH). have?

Accendra Health Inc (ACH) has 6500 emplpoyees as of July 05 2026.

What is Accendra Health Inc (ACH) market cap?

Today ACH has the market capitalization of 274.94M USD.